ClinicalTrials.gg
TerminatedNCT00980681Updated May 26, 2016Results posted

Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time-Of-Flight (TOF)

A Phase 3 interventional study of Dotarem and Time of Flight in Renal Disease, sponsored by Guerbet. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-26.

Sponsored by Guerbet · Phase 3, Interventional, and Diagnostic

Why this study was terminated
Lack of recruitment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
13
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 416 studies in Kidney Diseases with a site in United States — 64 open to participants now, 92 under way, 15 of them phase 3. Kidney Diseases · United States.

Enrollment
272nd of 318
13 · median 50
Started
2009
with 17 others
Phase 3
59 of 416
7 open now
Registered
115th of 416
by date

Among the 416 studies in Kidney Diseases with a site in United States, this one is the 272nd largest by enrollment of the 318 interventional ones that give a count, is one of 18 that started in 2009, is one of 59 in phase 3, and was the 115th registered.

Kidney Diseases

970 studies on the registry are indexed under Kidney Diseases; 184 are open to participants now.

Browse Kidney Diseases studies →

Open to participants now

64 of the 416 studies in Kidney Diseases with a site in United States are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 130 Kidney Diseases studies recruiting now, 76 (58%) set no upper age limit and 34 (26%) stop at 75 or younger; 26 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 416 studies in Kidney Diseases with a site in United States, or all of them as a file.
02

Study summary

The study will evaluate the efficacy and safety of Dotarem enhanced MRA compared to TOF MRA in patients suffering from renal arterial disease.

Read the detailed description

Each participant will undergo first a TOF MRA followed by a Dotarem-enhanced MRA.

03

Conditions studied

  • Renal Disease

Browse trials for

Keywords

  • Renal disease
  • Contrast agent
  • MRA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged more than 18 years
  • Strongly suspected of having renal arterial disease
  • Scheduled (or to be scheduled) to undergo arterial catheter-based X-ray angiography examination

Exclusion criteria

Exclusion Criteria:

  • Known grade IV or V chronic kidney disease (\<30 mL/min/1.73m²)
  • to MRI
  • Acute renal dysfunction within the 6 months preceding Dotarem®-enhanced MRA examination
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Dotarem

    Each subject will receive one injection of Dotarem 0.2ml/kg.

    Drug: Dotarem

  • Other
    Time Of Flight

    Each subject will undergo a TOF Magnetic Resonance Angiography

    Other: Time of Flight

Interventions

  • Each subject will receive one injection of Dotarem 0.2ml/kg

    Also known as: gadoteric acid, gadoterate meglumine

  • OtherTime of Flight

    Each subject will undergo a TOF MRA

06

What researchers measure

Primary outcomes

  1. Percent of Non Assessable Renal Artery Segments

    For each examination (TOF and Dotarem-enhanced MRA) the percent of non-assessable segments will be compared

    Time frame: 1 to 7 days

07

Results

Posted May 26, 2016
Limitations and caveats
The study was not completed due to poor enrolment. The statistical analysis was not perfomed.

Participant flow

The recruitment started in Sept 2009 and stopped in February 2010. Radiology departments from hospital or private practices were participating.

TOF MRA
Participant flow — TOF MRA
MilestoneTOF Followed by Dotarem-enhanced MRA
Started10
Completed10
Not completed0
Dotarem MRA
Participant flow — Dotarem MRA
MilestoneTOF Followed by Dotarem-enhanced MRA
Started10
Completed10
Not completed0

Outcome measures

PrimaryPercent of Non Assessable Renal Artery Segments

For each examination (TOF and Dotarem-enhanced MRA) the percent of non-assessable segments will be compared

Time frame:
1 to 7 days
Reported as:
Number · percentage of non-assessable segments
Percent of Non Assessable Renal Artery Segments
percentage of non-assessable segmentsDotarem-enhanced MRATime-Of-Flight MRA
Percent of Non Assessable Renal Artery Segments2520

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dotarem—0/10 (0%)4/10 (40%)
Time Of Flight—0/10 (0%)0/10 (0%)
Most frequent other events
Most frequent other events
EventDotaremTime Of Flight
Injection site painGeneral disorders2/100/10
Injection site inflammationGeneral disorders1/100/10
Abdominal painGastrointestinal disorders1/100/10
DiarrheaGastrointestinal disorders1/100/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TOF Followed by Dotarem-enhanced MRA
<=18 years0
Between 18 and 65 years7
>=65 years6
Age, Continuous
Age, Continuous(years)TOF Followed by Dotarem-enhanced MRA
Mean59 ± 16
Sex: Female, Male
Sex: Female, Male(Participants)TOF Followed by Dotarem-enhanced MRA
Female9
Male4
Region of Enrollment
Region of Enrollment(participants)TOF Followed by Dotarem-enhanced MRA
United States7
Canada6
08

Study locations

1 site
  • Guerbet LLC
    Bloomington, Indiana 47403, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 5 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2009
First posted
Sep 21, 2009
Start
Sep 2009
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results first posted
May 26, 2016
Last update
May 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00980681
Lead sponsor
Guerbet
Responsible party
Sponsor
First posted
Sep 21, 2009
Start date
Sep 2009
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
May 26, 2016
Last update
May 26, 2016

Study contacts

Pierre DESCHE, MD
study director · Guerbet

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gadoterate meglumine

Start the discussion